P2Y12 inhibitor monotherapy in complex percutaneous coronary intervention: A post-hoc analysis of SMART-CHOICE randomized clinical trial

• Published in: Cardiology journal Vol. 28; no. 6; pp. 855 - 863
• Main Authors: Roh, Ji Woong, Hahn, Joo-Yong, Oh, Ju-Hyeon, Chun, Woo Jung, Park, Yong Hwan, Jang, Woo Jin, Im, Eul-Soon, Jeong, Jin-Ok, Cho, Byung Ryul, Oh, Seok Kyu, Yun, Kyeong Ho, Cho, Deok-Kyu, Lee, Jong-Young, Koh, Young-Youp, Bae, Jang-Whan, Choi, Jae Woong, Lee, Wang Soo, Yoon, Hyuck Jun, Lee, Seung Uk, Cho, Jang Hyun, Choi, Woong Gil, Rha, Seung-Woon, Kim, Hee-Yeol, Lee, Joo Myung, Park, Taek Kyu, Yang, Jeong Hoon, Choi, Jin-Ho, Choi, Seung-Hyuck, Lee, Sang Hoon, Gwon, Hyeon-Cheol, Kim, Dong-Bin, Song, Young Bin
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 2021; Via Medica
• Subjects: Angioplasty; Cardiology; Cardiovascular disease; Clinical Cardiology; Clinical trials; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet Therapy; Enzymes; Heart attacks; Hemorrhage - chemically induced; Hospitals; Humans; Internal medicine; Ischemia; Medical schools; Medicine; Percutaneous Coronary Intervention - adverse effects; Platelet Aggregation Inhibitors - adverse effects; Purinergic P2Y Receptor Antagonists - adverse effects; Stents; Stroke; Treatment Outcome; clopidogrel; percutaneous coronary intervention; high-risk
• ISSN: 1897-5593; 1898-018X
• DOI: 10.5603/CJ.A2021.0101

It remains unclear whether P2Y12 monotherapy, especially clopidogrel, following short-duration dual antiplatelet therapy (DAPT) is associated with favorable outcomes in patients undergoing complex percutaneous coronary intervention (PCI). Therefore, this study analyzed the efficacy and safety of P2Y12 inhibitor monotherapy, mostly clopidogrel (78%), in complex PCI following short-term DAPT. The post-hoc analysis of the SMART-CHOICE trial involving 2,993 patients included 498 cases of complex PCIs, defined by at least one of the following features: 3 vessels treated, ≥ 3 stents implanted, ≥ 3 lesions treated, bifurcation with ≥ 2 stents implanted, and a total stent length of ≥ 60 mm. The primary endpoint was major adverse cardiac and cerebrovascular event (MACCE), defined as the composite of all-cause death, myocardial infarction, and stroke. The primary safety endpoint included bleeding, defined as Bleeding Academic Research Consortium (BARC) types 2 to 5. Complex PCI group had a higher risk of MACCE (4.0% vs. 2.3%, hazard ratio [HR] = 1.74, 95% confidence interval [CI]: 1.05-2.89, p = 0.033) and a similar risk of BARC types 2-5 bleeding (2.6% vs. 2.6%, HR = 1.02, 95% CI: 0.56-1.86, p = 0.939) compared with those without complex PCIs. Patients undergoing complex PCIs, followed by P2Y12 inhibitor monotherapy and 12 months of DAPT exhibited similar rates of MACCE (3.8% vs. 4.2%, HR = 0.92, 95% CI: 0.38-2.21, p = 0.853). P2Y12 inhibitor monotherapy, mostly clopidogrel, following 3 months of DAPT did not increase ischemic events in patients with complex PCIs.